These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 1366610)

  • 1. New strategies for the design of catalytic antibodies.
    Janda KD
    Biotechnol Prog; 1990; 6(3):178-81. PubMed ID: 1366610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Large rate accelerations in antibody catalysis by strategic use of haptenic charge.
    Thorn SN; Daniels RG; Auditor MT; Hilvert D
    Nature; 1995 Jan; 373(6511):228-30. PubMed ID: 7816136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new strategy for the generation of catalytic antibodies.
    Shokat KM; Leumann CJ; Sugasawara R; Schultz PG
    Nature; 1989 Mar; 338(6212):269-71. PubMed ID: 2922053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis for antibody catalysis of a disfavored ring closure reaction.
    Gruber K; Zhou B; Houk KN; Lerner RA; Shevlin CG; Wilson IA
    Biochemistry; 1999 Jun; 38(22):7062-74. PubMed ID: 10353817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toward bifunctional antibody catalysis.
    Kikuchi K; Hannak RB; Guo MJ; Kirby AJ; Hilvert D
    Bioorg Med Chem; 2006 Sep; 14(18):6189-96. PubMed ID: 16782349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tech.Sight. Antibody design by man and nature.
    Wentworth P
    Science; 2002 Jun; 296(5576):2247-9. PubMed ID: 12077422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of three selenium-containing catalytic antibodies with high catalytic efficiency using a novel hapten design method.
    Su D; Ren X; You D; Li D; Mu Y; Yan G; Zhang Y; Luo Y; Xue Y; Shen J; Liu Z; Luo G
    Arch Biochem Biophys; 2001 Nov; 395(2):177-84. PubMed ID: 11697854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of peptide mimotopes for the fluorescein hapten binding of monoclonal antibody B13-DE1.
    Böttger V; Peters L; Micheel B
    J Mol Recognit; 1999; 12(3):191-7. PubMed ID: 10398409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of hapten binding and catalytic determinants in a family of catalytic antibodies.
    Ulrich HD; Schultz PG
    J Mol Biol; 1998 Jan; 275(1):95-111. PubMed ID: 9451442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibodies distinguish synthetic peptides that differ in one chemical group.
    Motté P; Alberici G; Ait-Abdellah M; Bellet D
    J Immunol; 1987 May; 138(10):3332-8. PubMed ID: 2437187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic and fluorescence studies of affinity maturation in related antibodies.
    Pauyo T; Hilinski GJ; Chiu PT; Hansen DE; Choi YJ; Ratner DI; Shah-Mahoney N; Southern CA; O'Hara PB
    Mol Immunol; 2006 Mar; 43(7):812-21. PubMed ID: 16137768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Catalytic antibodies that hydrolyze (-)-cocaine obtained by a high-throughput procedure.
    Cashman JR; Berkman CE; Underiner GE
    J Pharmacol Exp Ther; 2000 Jun; 293(3):952-61. PubMed ID: 10869397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A selenium-containing catalytic antibody with Type I deiodinase activity.
    Lian G; Ding L; Chen M; Liu L; Zhao D; Ni J
    Biochem Biophys Res Commun; 2001 May; 283(5):1007-12. PubMed ID: 11355872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanistic analysis of the phosphonate transition-state analogue-derived catalytic and non-catalytic antibody.
    Nishi Y; Yamamoto N; Shimazaki K; Takahashi-Ando N; Kakinuma H; Jialin S; Ruzheinikov SN; Muranova TA; Rice DW; Kajihara Y
    J Biochem; 2007 Oct; 142(4):421-33. PubMed ID: 17981825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Directed evolution governed by controlling the molecular recognition between an abzyme and its haptenic transition-state analog.
    Takahashi-Ando N; Kakinuma H; Fujii I; Nishi Y
    J Immunol Methods; 2004 Nov; 294(1-2):1-14. PubMed ID: 15604011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening strategies for catalytic antitransition-state analog antibodies.
    Tramontano A
    Methods Mol Biol; 1995; 51():237-50. PubMed ID: 7581701
    [No Abstract]   [Full Text] [Related]  

  • 17. The interplay between binding energy and catalysis in the evolution of a catalytic antibody.
    Ulrich HD; Mundorff E; Santarsiero BD; Driggers EM; Stevens RC; Schultz PG
    Nature; 1997 Sep; 389(6648):271-5. PubMed ID: 9305839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Catalytic antibodies: hapten design strategies and screening methods.
    Xu Y; Yamamoto N; Janda KD
    Bioorg Med Chem; 2004 Oct; 12(20):5247-68. PubMed ID: 15388154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A catalytic antibody against a tocopherol cyclase inhibitor.
    Manetsch R; Zheng L; Reymond MT; Woggon WD; Reymond JL
    Chemistry; 2004 May; 10(10):2487-506. PubMed ID: 15146522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Squaric monoamide monoester as a new class of reactive immunization hapten for catalytic antibodies.
    Xu Y; Yamamoto N; Ruiz DI; Kubitz DS; Janda KD
    Bioorg Med Chem Lett; 2005 Oct; 15(19):4304-7. PubMed ID: 16046128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.